Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab Every 4 Weeks in Relapsed/Refractory CTCL
2024-515921-27-00Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Kyowa Kirin. Primary endpoints: Treatment-emergent adverse events and Changes in safety assessments. Started Oct 2024; status: completed.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2024-515921-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515921-27-00.